Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report

Figure 1 Representative images from computed tomography and renal ultrasonography. A: Computed tomography imaging of the body; B: Representative image of multiple cysts on bilateral kidneys indicated by arrows; C: The largest cyst image on the right kidney indicated by arrows; D: The largest cyst image on the left kidney indicated by arrows.

Figure 2 Representative images of venous thrombosis in lower extremity by ultrasonography. A: Venous thrombosis in the right lower extremity before treatment shown by arrows; B: Venous thrombosis in the left lower extremity before treatment shown by arrows; C: Venous thrombosis disappeared in the right lower extremity after treatment; D: Venous thrombosis disappeared in the left lower extremity after treatment.

Figure 3 Laboratory test data. A: eGFR fluctuation graph during the treatment. At the treatment initiation, eGFR was 14.43 ml/min/1.73 m², it was raised to 37.32 ml/min/1.73 m² after 15 months of treatment; B: Serum creatinine change graph. At the start of treatment, creatinine was 330.5 μmol/L exceeding normal range (35-106 μmol/L), which indicated that there was an acute kidney injury. The creatinine was dramatically reduced to 174.4 μmol/L after 3 months of treatment; C: Uric acid change graph. At the start of treatment, uric acid was 498 μmol/L over normal range (150-420 μmol/L), after a few months of treatment, it was reduced to a normal range; D: Hemoglobin change graph. At the treatment initiation, hemoglobin was 109 g/L, it was within normal range (130-175 g/L) after 6 months of treatment.